Clinical Research Of The Rosiglitazone For The Prevention Of The Patients With Steroid Diabets

Background and objectiveBecause of resisting inflammation,the glucocorticoid is widely used in clinic.It not only brings therapeutic action but also brings side effect.Steroid diabetes is one of common side effect.Steroid diabetes is a special sugar metabolism chaotic syndrome,and it is a secondly diabetes mellitus which is initiated by too much glucocorticoid caused by endogenous factor or exogenous factor.At present there is a lot of study and research about the treatment of steroid diabetes,but the study and research about the prevention of steroid diabetes is less.To search effective method for the prevention of steroid diabetes is important for raising living quality.The Rosiglitazone is PPAR-γagonism.It can activate PPAR-γ,and strengthen the effect of Insulin in the level of transcription.The Rosiglitazone enhance insulin secretion and reverse beta cell defects for the treatment of steroid diabetes.To observe the efficiency of the Rosiglitazone in the prevention of steroid diabetes,and to explore the function of the Rosiglitazone in the prevention of steroid diabetes at present research.Methods25 cases belong to experiment group were treated with both prednisone (≥1mg.kg^-1.d^-1) and Rosiglitazone(4mg.d^-1).35 cases belong to comparion group were treated with prednisone(1mg.kg^-1.d^-1).Both age and sex in comparion group were accord with that of experiment group.All cases were assessed by measuring oral glucose tolerance test,HbA₁c,and C-P release test at baseline and after treatment for 8 weeks.In this research the age of All cases was bwteen 16 and 60,without diabetes mellitus,hypertension or that of the family clan.All cases had normal glucose tolerance and liver function.They didn't treat with prednisone or had not treat with prednisone for one month,and they would treat with prednisone(≥1mg.kg^-1.d^-1).Results1.the results of OGTT:Fasting blood sugar at baseline was higer than that of after treatment for 8 weeks both in experiment group and in comparion group(P＜0.05).In experiment group,there was no statistic difference of the blood sugar of taking oral glucose 30,60,120,180 minutes between at baseline and after treatment for 8 weeks(P＞0.05).In comparion group,The blood sugar of takeing oral glucose 60,120,180 minutes of after treatment for 8 weeks were higher than that of baseline(P＜0.05).After treatment for 8 weeks,the blood sugar of taking oral glucose 120,180 minutes of comparion group were higer than that of experiment group(P＜0.05).2.the results of HbA₁c:In experiment group,HbA₁c of baseline was not higher than that of treatment for 8 weeks(P＞0.05).In comparion group,HbA₁c of treatment for 8 weeks was higher than that of baseline of comparion group(P＜0.05).After treatment for 8 weeks,HbA₁c of comparion group was higer than that of experiment group(P＜0.05).3.the results of C-P release test:The area under the C peptide curve for the oral glucose tolerance test after treatment for 8 weeks was not higher than that of baseline both in experiment group and comparion group(P＞0.05).ConclusionThe Rosiglitazone may be an effective drug in the prevention of steroid diabetes.